Clinical trials: Mental Disorders, Severe
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
Assessing Symptomatic Clinical Episodes in Depression
Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.
- Trial name
- ASCEND (NCT03595579)
- Testing
- AXS-05, Bupropion
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Axsome Therapeutics, Inc.
Attention Deficit Disorder With Hyperactivity
Treatment of Severe Childhood Aggression (The TOSCA Study)
This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00796302
- Testing
- Methylphenidate HCl, Risperidone, Parent Management Training (PMT)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- Michael Aman
Major Depressive Disorder
ECT Pulse Amplitude and Medial Temporal Lobe Engagement
Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes will respond to treatment and people will improve their…
- Trial name
- NCT02999269
- Testing
- MECTA Spectrum 5000Q Amplitude
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of New Mexico
Depression
Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
This study will examine multiple carefully selected clinical and biological markers, using both existing state-of-the-art technologies as well as pioneering, innovative approaches.
- Trial name
- EMBARC (NCT01407094)
- Testing
- Sertraline, BupropionXL
- Where
- 4 sites in United States
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838681
- Testing
- Brexpiprazole, ADT
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,986 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder (MDD)
Preventing Relapse After Successful Electroconvulsive Therapy for Depression
The present project is designed to study two promising relapse prevention strategies in an RCT. This will be the first project worldwide to study the effects of a personalized ECT treatment algorithm in the continuation phase of…
- Trial name
- PRASED (NCT06751875)
- Testing
- Lithium
- Where
- Belgium
- Volunteers
- 96 people
- Sponsor
- Universiteit Antwerpen
Major Depressive Disorder
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Iloperidone is an atypical antipsychotic drug, FDA-approved for the acute treatment of schizophrenia in adults in 2009 (Marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating…
- Trial name
- NCT01464229
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maurizio Fava, MD
Alzheimer Disease
Bryostatin Treatment of Moderately Severe Alzheimer's Disease
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
- Trial name
- NCT04538066
- Testing
- Bryostatin 1
- Where
- 19 sites in United States
- Volunteers
- 122 people
- Sponsor
- Neurotrope Bioscience, Inc.
Major Depressive Disorder
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration.
- Trial name
- NCT04711005
- Testing
- (2R,6R)-Hydroxynorketamine hydrochloride
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
This study will evaluate changes in brain energy metabolism due to treatment with escitalopram in people with major depressive disorder.
- Trial name
- NCT00183677
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function
The purpose of this study is to understand the effectiveness of a ten-week internet-based cognitive behavioral therapy (iCBT) treatment on improving depressive symptoms, coping and resilience skills, and cognitive processing.
- Trial name
- iCBT (NCT01598922)
- Testing
- Internet Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Mclean Hospital
Bipolar Depression, Suicidal Ideas
Sequential Therapy for the Treatment of Severe Bipolar Depression.
NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or…
- Conditions
- Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
- Trial name
- STABIL-B (NCT02974010)
- Testing
- NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- NeuroRx, Inc.
Depression, Major Depressive Disorder
eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients
The objective of this randomized controlled trial is to evaluate whether the investigators modernized IMPACT intervention for depression (eIMPACT), delivered before the onset of cardiovascular disease (CVD), reduces the risk of…
- Conditions
- Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms
- Trial name
- NCT02458690
- Testing
- Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Indiana University
Major Depression
Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment
The antidepressant medications are among the most commonly prescribed pharmacological agents in patients with mood and anxiety disorder.
- Trial name
- NCT03927950
- Testing
- escitalopram, bupropion
- Where
- Estonia
- Volunteers
- 135 people
- Sponsor
- University of Tartu
Depressive Disorder, Major
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
This multi-centre study will follow a randomised, double-blind, parallel-group, active-controlled design and will evaluate the efficacy, safety and tolerability of bupropion extended-release (XL) (300 mg/day) compared with…
- Trial name
- NCT02191397
- Testing
- Bupropion, Escitalopram
- Where
- 20 sites in China
- Volunteers
- 534 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for severe depression.
- Trial name
- NCT00422162
- Testing
- Duloxetine hydrochloride
- Where
- 35 sites in France, Italy and 2 more
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company
Dementia, Dementia, Vascular
Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
Millions of Americans have late-stage Alzheimer's and related dementias (ADRD), causing suffering due to loss of awareness of self and family, progressive dependency, physical and neuropsychiatric symptoms, and physical…
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal
- Trial name
- ADRD-PC (NCT04948866)
- Testing
- ADRD-PC Program
- Where
- 5 sites in United States
- Volunteers
- 884 people
- Sponsor
- University of North Carolina, Chapel Hill
Pulmonary Disease, Chronic Obstructive, Major Depression
Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Approximately 20% of patients with chronic obstructive pulmonary disease (COPD) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity.
- Trial name
- NCT00151372
- Testing
- Treatment Adherence Intervention, Enhanced Care
- Where
- 3 sites in United States
- Volunteers
- 141 people
- Sponsor
- Weill Medical College of Cornell University
Diabetic Neuropathies, Depressive Disorder, Major
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP) patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 mg once daily (QD) leads to a…
- Trial name
- NCT00844194
- Testing
- Duloxetine 60 mg QD, Duloxetine 30 mg QD, Duloxetine 90 mg QD
- Where
- 25 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim